Session: SAT 532-553-Hyperandrogenic Disorders
Poster Board SAT-545
Methods : 109 women with PCOS were randomized to receive oral treatment with an OCP containing ethinyl-estradiol plus cyproterone acetate (OCP 1), with an OCP containing ethinylestradiol plus drospirenone (OCP 2) or with metformin (850 mg twice daily) for 6 months. Serum AGEs levels, hormonal and metabolic parameters as well as C-reactive protein levels were determined at baseline,after three months and after six months of treatment.
Results: The three groups had similar age and BMI at baseline. Serum AGEs levels at baseline were also comparable between the three groups. The mean BMI was increased at 6 months in groups A and B ,but was decreased in group C. Serum AGEs levels were significantly reduced in all groups at 6 months of treatment compared to baseline , but the percent of reduction was significantly greater in group C than in group A and group B. The percent decrease of serum AGEs correlated only with baseline BMI , but was independent of the BMI change,as well as other metabolic,hormonal and inflammatory parameters.
Conclusions: For the first time, metformin is shown to be superior tο OCPs in reducing circulating levels of AGEs. Thus, metformin may be superior to OCPs in alleviating the cardiovascular risk associated with PCOS. This beneficial effect appears to be independent of BMI changes observed in all treatment groups and specifically, the weight reducing effect of metformin.
Nothing to Disclose: CC, CP, SL, EM, AK, IK, DP, ED
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters